Mindmed Acquires Opioid Addiction Drug Candidate Based On The Natural Psychedelic Ibogaine

Mind Medicine Inc. (Mindmed), a leading neuro-pharmaceutical company focused on discovering and developing treatment medication based on psychedelics, has finalized the acquisition of the 18-MC drug development program, an anti-addictive molecule that was previously funded by the National Institute on Drug Abuse (NIDA). Mindmed acquired the project from Savant HWP Inc., whose leadership team of top researchers and drug developers will also join the company.

18-MC is based on the natural psychedelic substance, ibogaine, and is focused on addressing the opioid crisis and other forms of addiction. Historically, ibogaine has been successful in treating heroin addiction . . .